Home » Newsletters » The Carlat Psychiatry Report

The Carlat Psychiatry Report

Antipsychotic Update (January) | 2013

View Archived Issues

The Psychosis Prodrome

January 1, 2013

Rachel Loewy, PhD and Demian Rose, PhD, MD

At the crossroads of these experiences lies the concept of the psychosis prodrome and early intervention/prevention efforts. But without evidence of a florid psychotic episode, when should one intervene? Read More

Atypical Antipsychotics: Where is the Science, Where is the Evidence?

January 1, 2013

P Ken Gillman, MBBS

Any psychiatrist who has practiced during the last decade has probably written more than a few prescriptions for an atypical antipsychotic. But do these drugs provide any clear advantages over their predecessors? Read More

Old Versus New Antipsychotics

January 1, 2013

Robert Rosenheck, MD

Are the benefits of atypical antipsychotics based in reality? Dr. Rosenheck explains the stark difference between the SGAs of pharmaceutical myth and what has been proven with actual science. Read More

Some Popular Antipsychotics May Not be Effective in Patients over 40

January 1, 2013

Glen Spielmans, PhD

Atypical antipsychotics are widely prescribed for a number of psychiatric diagnoses, but their real-world effectiveness has rarely been evaluated in anything other than short-term trials. A recently published study finds that four commonly used antipsychotics (aripiprazole [Abilify], olanzapine [Zyprexa], quetiapine [Seroquel], and risperidone [Risperdal]), when used in patients over age 40 with schizophrenia or psychosis associated with other conditions, may not be effective—and cause frequent side effects. Read More